A5021572863- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Statistical Methods in Clinical Trials
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- COVID-19 and healthcare impacts
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Chronic Lymphocytic Leukemia Research
- Angiogenesis and VEGF in Cancer
- Cancer-related Molecular Pathways
- Liver physiology and pathology
- PI3K/AKT/mTOR signaling in cancer
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Urinary Tract Infections Management
- Renal and related cancers
Hospital Sírio-Libanês
2015-2025
Eastern Cooperative Oncology Group
2022-2024
The University of Texas MD Anderson Cancer Center
2013-2023
Hospital São Paulo
2022
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2020
Instituto de Oncologia do Paraná
2016-2018
Instituto do Câncer do Estado de São Paulo
2017
University of California, San Diego
2015-2016
American Society of Clinical Oncology
2015-2016
Universidade Estadual de Campinas (UNICAMP)
2005-2015
This study aimed to assess MET amplification among different cancers, association with clinical factors and genetic aberrations targeted therapy response modifications.From May 2010 November 2012, samples from patients advanced tumors referred the MD Anderson Phase I Clinic were analyzed for gene by FISH. Patient demographic, histologic characteristics, molecular outcomes in phase protocols compared per status.Of 1,115 patients, 29 (2.6%) had amplification. The highest prevalence was adrenal...
FBXW7 is a tumor suppressor gene responsible for the degradation of several proto-oncogenes. Preclinical data suggest that mutations sensitize cells to mTOR inhibitors. Clinicopathologic characteristics cancer patients with and their responses inhibitors remain unknown.Using multiplex panels we evaluated how mutation affected phenotype referred phase I clinic starting January 2012. Whenever possible positive were treated regimens containing an outcomes reviewed.FBXW7 detected in 17 418...
Accessibility to next-generation sequencing (NGS) technologies has enabled the profiling of microbial communities living in distinct habitats. 16S ribosomal RNA (rRNA) gene is widely used for microbiota with NGS technologies. Since most platforms generate short reads, full-length rRNA impractical. Therefore, choosing which hypervariable region sequence critical studies. All nine regions are taxonomically informative, but due variability performance specific clades, ideal will depend on...
Background The phosphatidylinositol 3‐kinase (PI3K) pathway is frequently altered in cancer. This report describes the landscape of PI3K alterations solid tumors as well co‐alterations serving potential resistance/attenuation mechanisms. Methods Consecutive samples were analyzed a commercial Clinical Laboratory Improvement Amendment‐certified laboratory using comprehensive genomic profiling performed by next‐generation sequencing (315 genes). evaluated included Erb‐B2 receptor tyrosine...
We analyzed clinical associations of MET alterations in the plasma patients with diverse malignancies. Digital sequencing circulating tumor DNA (ctDNA) (54–70 genes) was performed 438 patients; 263 also had tissue (182–315 genes). The most represented types were gastrointestinal (28.1%), brain (24.9%), and lung (23.2%). Most (71.2%) recurrent/metastatic disease. observed 31 (7.1%) correlated bone metastasis (P = 0.007), TP53 0.001) PTEN 0.003) abnormalities, an increased number (median, 4 vs...
Cancer demands precise evaluation and accurate timely assessment of response to treatment. Imaging must be performed early during therapy allow adjustments the course For decades, cross-sectional imaging provided these answers, showing responses treatment through changes in tumor size. However, with emergence immune checkpoint inhibitors, complex patterns were revealed that have quickly highlighted limitations this approach. Patterns beyond size been recognized include cystic degeneration,...
Abstract Background Phyllodes tumors are uncommon breast that account for less than 0.5% of all malignancies. After metastases develop, the prognosis is poor, with very few patients living more 1 year. The biology this unusual cancer not understood and, consequently, no potential targets treatments currently available. There has been an exponential increase in number commercially available tumor profiling services. Herein, we report a case metastatic malignant phyllodes which comprehensive...
373 Background: During the COVID-19 pandemic resources from Brazilian Public Health System (BPHS) were directed to treatment of COVID-19. The impact on prostate cancer in Brazil has not yet been rigorously evaluated. Methods: We compared number radical prostatectomies (RP), radiotherapy (RT), and hormonal (HT) chemotherapy (CT) treatments March 1st, 2020 February 29th, 2022, with that two pre-pandemic years (March 2018, 28th, 2020). Additionally, we evaluated post-pandemic period 2022 2024....
178 Background: Sequencing androgen-receptor signaling inhibitors (ARSi) has limited activity in metastatic castration-resistant prostate cancer (mCRPC). Bipolar Androgen Therapy (BAT), consisting of supraphysiological doses exogenous testosterone, followed by a decline to castrate levels, shown benefit subset patients (pts) with mCRPC, the downregulation AR therapeutic vulnerability which led resensitization ARSi trials. We hypothesize that BAT could significantly enhance efficacy...
Abstract Background Immune checkpoint inhibitors (ICIs) have significantly advanced cancer therapy, yet their efficacy in tumors with low tumor mutational burden (TMB) remains suboptimal. In this study, we aimed to elucidate the impact of somatic mutations on overall survival (OS) TMB-low patients treated ICIs and explore potential for personalized treatment selection through machine learning. Methods We conducted a comprehensive analysis 1172 (TMB < 10 per megabase) receiving ICIs,...
// Denis Leonardo Jardim 1 , Maria Schwaederle 2 David S. Hong 3 Razelle Kurzrock Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil Center for Personalized Cancer Therapy and Division Hematology University California, San Diego, CA, USA Investigational Therapeutics (Phase I Trials Program), The Texas MD Anderson Center, Houston, TX, Correspondence to: Jardim, email: jardimde@gmail.com Keywords: drug development, precision medicine, pharmacoeconomics, biomarkers, FDA...
// Denis L. Fontes Jardim 1 , Debora de Melo Gagliato Gerald S. Falchook Filip Janku Ralph Zinner Jennifer J. Wheler Vivek Subbiah Sarina A. Piha-Paul Siqing Fu Mariela Blum Murphy 2 Jaffer Ajani Chad Tang 3 Kenneth Hess 4 Stanley R. Hamilton Sinchita Roy-Chowdhuri Razelle Kurzrock 5 Funda Meric-Bernstam David Hong Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University Texas MD Anderson Center, Houston, USA Gastrointestinal Medical Oncology,...
Abstract Background We describe the landscape of cyclin and interactive gene pathway alterations in 190,247 solid tumors. Methods Using comprehensive genomic profiling (315 genes, >500× coverage), samples were analyzed for activating/sensitizing genes (CDK4 amplification, CDK6 CCND1, CCND2, CCND3, CDKN2B [loss], CDKN2A SMARCB1), hormone (estrogen receptor 1 [ESR1], androgen [AR]), co-alterations leading to inhibitor therapeutic resistance (RB1 CCNE1). Results Alterations at least one...